Glial Cell Expression of PD-L1

被引:25
|
作者
Chauhan, Priyanka [1 ]
Lokensgard, James R. [1 ]
机构
[1] Univ Minnesota, Dept Med, Neurovirol Lab, Minneapolis, MN 55455 USA
关键词
PD-L1; glia; central nervous system; T-CELLS; MICROGLIAL ACTIVATION; B7-RELATED MOLECULE; IMMUNE-RESPONSES; B7-H1; REGULATION; NITRIC-OXIDE; SYSTEM; CONTRIBUTES; MECHANISM; ANTIBODY;
D O I
10.3390/ijms20071677
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The programmed death (PD)-1/PD-L1 pathway is a well-recognized negative immune checkpoint that results in functional inhibition of T-cells. Microglia, the brain-resident immune cells are vital for pathogen detection and initiation of neuroimmune responses. Moreover, microglial cells and astrocytes govern the activity of brain-infiltrating antiviral T-cells through upregulation of PD-L1 expression. While T-cell suppressive responses within brain are undoubtedly beneficial to the host, preventing cytotoxic damage to this vital organ, establishment of a prolonged anti-inflammatory milieu may simultaneously lead to deficiencies in viral clearance. An immune checkpoint blockade targeting the PD-1: PD-L1 (B7-H1; CD274) axis has revolutionized contemporary treatment for a variety of cancers. However, the therapeutic potential of PD1: PD-L1 blockade therapies targeting viral brain reservoirs remains to be determined. For these reasons, it is key to understand both the detrimental and protective functions of this signaling pathway within the brain. This review highlights how glial cells use PD-L1 expression to modulate T-cell effector function and limit detrimental bystander damage, while still retaining an effective defense of the brain.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] PD-L1 expression in cell blocks
    Erdogan-Durmus, S.
    Buyukpinarbasili, N.
    VIRCHOWS ARCHIV, 2021, 479 : S198 - S198
  • [2] Comparing the performance of three PD-L1 antibodies for PD-L1 expression in renal cell carcinoma
    Park, S.
    Wi, Y. C.
    Shin, S.
    Jang, K.
    VIRCHOWS ARCHIV, 2019, 475 : S181 - S182
  • [3] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [4] PD-L1 expression in anaplastic large cell lymphoma
    Kong, Jianping
    Dasari, Surendra
    Feldman, Andrew L.
    MODERN PATHOLOGY, 2020, 33 (06) : 1232 - 1233
  • [5] PD-L1 expression in small cell neuroendocrine carcinomas
    Schultheis, Anne M.
    Scheel, Andreas H.
    Ozretic, Luka
    George, Julie
    Thomas, Roman K.
    Hagemann, Thorsten
    Zander, Thomas
    Wolf, Juergen
    Buettner, Reinhard
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 421 - 426
  • [6] PD-L1 Expression in Chromophobe Renal Cell Carcinomas
    Ta, Robert
    Mahdi, Zaid
    Calagua, Carla
    Ye, Huihui
    Lin, Douglas
    MODERN PATHOLOGY, 2019, 32
  • [7] PD-L1 Expression in Adult Granulosa Cell Tumors
    Okoye, Ekene
    Khazaeian, Kamyar
    Tracie, Koen
    Mullick, Seema
    Coffey, Donna
    Deavers, Michael
    LABORATORY INVESTIGATION, 2018, 98 : 442 - 442
  • [8] PD-L1 Expression in Small Cell Lung Cancer
    Yasuda, Yuto
    Ozasa, Hiroaki
    Kim, Young Hak
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : E40 - E41
  • [9] PD-L1 expression in small cell lung cancer
    Komiya, Takefumi
    Madan, Rashna
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (13) : 1853 - 1855
  • [10] PD-L1 expression in tongue squamous cell carcinoma
    Akisada, Naoki
    Nishimoto, Kohei
    Takao, Soshi
    Gion, Yuka
    Marunaka, Hidenori
    Tachibana, Tomoyasu
    Makino, Takuma
    Miki, Kentaro
    Akagi, Yusuke
    Tsumura, Munechika
    Toji, Tomohiro
    Yoshino, Tadashi
    Nishizaki, Kazunori
    Orita, Yorihisa
    Sato, Yasuharu
    MEDICAL MOLECULAR MORPHOLOGY, 2021, 54 (01) : 52 - 59